MKI67 and breast carcinoma: showed thatthe Ki67 labeling index is useful in distinguishing between the luminal Aand luminal B subtypes.4The clinical application of a Ki67 cutoff in breast cancer has beenextensively investigated,11–21 but few studies to date haveexamined the clinical significance of Ki67 expression as a continuousvariable.21 Inthe present study, we explored the clinical characteristics and outcomes ofa retrospective cohort of patients using Ki67 expression as a dichotomous orcontinuous variable.